COMPAZINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral tablet small-molecule antipsychotic and antiemetic approved in 1956. The exact mechanism of action and full indication set are not specified in available data, but the drug is used primarily for nausea, vomiting, and psychiatric conditions. It represents a legacy product in GSK's portfolio with significant historical clinical use.
LOE Approaching
As LOE approaches, brand teams will shift focus from growth maintenance to managed decline; expect smaller specialized teams focused on legacy care and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMPAZINE represents a niche legacy product with zero current linked job openings, reflecting its mature, declining lifecycle stage. Career advancement opportunities are limited; roles focus on maintaining existing market share and managing the transition to generic/biosimilar alternatives.
Brand ManagerField Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.